Cargando…

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

INTRODUCTION: Type I interferons (IFNs) are implicated in the pathogenesis of systemic sclerosis (SSc). MEDI-546 is an investigational human monoclonal antibody directed against the type I IFN receptor. This Phase 1 study evaluated the safety/tolerability, pharmacokinetics (PK), immunogenicity, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Avram, Geppert, Thomas, Schiopu, Elena, Frech, Tracy, Hsu, Vivien, Simms, Robert W, Peng, Stanford L, Yao, Yihong, Elgeioushi, Nairouz, Chang, Linda, Wang, Bing, Yoo, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978926/
https://www.ncbi.nlm.nih.gov/pubmed/24559157
http://dx.doi.org/10.1186/ar4492
_version_ 1782310651830468608
author Goldberg, Avram
Geppert, Thomas
Schiopu, Elena
Frech, Tracy
Hsu, Vivien
Simms, Robert W
Peng, Stanford L
Yao, Yihong
Elgeioushi, Nairouz
Chang, Linda
Wang, Bing
Yoo, Stephen
author_facet Goldberg, Avram
Geppert, Thomas
Schiopu, Elena
Frech, Tracy
Hsu, Vivien
Simms, Robert W
Peng, Stanford L
Yao, Yihong
Elgeioushi, Nairouz
Chang, Linda
Wang, Bing
Yoo, Stephen
author_sort Goldberg, Avram
collection PubMed
description INTRODUCTION: Type I interferons (IFNs) are implicated in the pathogenesis of systemic sclerosis (SSc). MEDI-546 is an investigational human monoclonal antibody directed against the type I IFN receptor. This Phase 1 study evaluated the safety/tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple intravenous doses of MEDI-546 in adults with SSc. METHODS: Subjects (≥18 years) with SSc were enrolled in an open-label, dose-escalation study to receive single (0.1, 0.3, 1.0, 3.0, 10.0, or 20.0 mg/kg), or 4 weekly intravenous doses (0.3, 1.0, or 5.0 mg/kg/week) of MEDI-546. Subjects were followed for 12 weeks. Safety assessments included adverse events (AEs), laboratory results, and viral monitoring. Blood samples were collected from all subjects for determination of PK, presence of anti-drug antibodies (ADAs), and expression of type I IFN-inducible genes. RESULTS: Of 34 subjects (mean age 47.4 years), 32 completed treatment and 33 completed the study. Overall, 148 treatment-emergent AEs (TEAEs) were reported (68.9% mild, 27.7% moderate). TEAEs included one grade 1 infusion reaction (5.0 mg/kg/week multiple dose). Of 4 treatment-emergent serious AEs (skin ulcer, osteomyelitis, vertigo, and chronic myelogenous leukemia (CML)), only CML (1.0 mg/kg/week multiple dose) was considered possibly treatment-related. MEDI-546 exhibited non-linear PK at lower doses. ADAs were detected in 5 subjects; no apparent impact on PK was observed. Peak inhibition of the type I IFN signature in whole blood was achieved within 1 day and in skin after 7 days. CONCLUSION: The safety/tolerability, PK, and PD profiles observed in this study support further clinical development of MEDI-546. TRIAL REGISTRATION: ClinicalTrials.gov NCT00930683
format Online
Article
Text
id pubmed-3978926
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39789262014-04-09 Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study Goldberg, Avram Geppert, Thomas Schiopu, Elena Frech, Tracy Hsu, Vivien Simms, Robert W Peng, Stanford L Yao, Yihong Elgeioushi, Nairouz Chang, Linda Wang, Bing Yoo, Stephen Arthritis Res Ther Research Article INTRODUCTION: Type I interferons (IFNs) are implicated in the pathogenesis of systemic sclerosis (SSc). MEDI-546 is an investigational human monoclonal antibody directed against the type I IFN receptor. This Phase 1 study evaluated the safety/tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple intravenous doses of MEDI-546 in adults with SSc. METHODS: Subjects (≥18 years) with SSc were enrolled in an open-label, dose-escalation study to receive single (0.1, 0.3, 1.0, 3.0, 10.0, or 20.0 mg/kg), or 4 weekly intravenous doses (0.3, 1.0, or 5.0 mg/kg/week) of MEDI-546. Subjects were followed for 12 weeks. Safety assessments included adverse events (AEs), laboratory results, and viral monitoring. Blood samples were collected from all subjects for determination of PK, presence of anti-drug antibodies (ADAs), and expression of type I IFN-inducible genes. RESULTS: Of 34 subjects (mean age 47.4 years), 32 completed treatment and 33 completed the study. Overall, 148 treatment-emergent AEs (TEAEs) were reported (68.9% mild, 27.7% moderate). TEAEs included one grade 1 infusion reaction (5.0 mg/kg/week multiple dose). Of 4 treatment-emergent serious AEs (skin ulcer, osteomyelitis, vertigo, and chronic myelogenous leukemia (CML)), only CML (1.0 mg/kg/week multiple dose) was considered possibly treatment-related. MEDI-546 exhibited non-linear PK at lower doses. ADAs were detected in 5 subjects; no apparent impact on PK was observed. Peak inhibition of the type I IFN signature in whole blood was achieved within 1 day and in skin after 7 days. CONCLUSION: The safety/tolerability, PK, and PD profiles observed in this study support further clinical development of MEDI-546. TRIAL REGISTRATION: ClinicalTrials.gov NCT00930683 BioMed Central 2014 2014-02-24 /pmc/articles/PMC3978926/ /pubmed/24559157 http://dx.doi.org/10.1186/ar4492 Text en Copyright © 2014 Goldberg et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research Article
Goldberg, Avram
Geppert, Thomas
Schiopu, Elena
Frech, Tracy
Hsu, Vivien
Simms, Robert W
Peng, Stanford L
Yao, Yihong
Elgeioushi, Nairouz
Chang, Linda
Wang, Bing
Yoo, Stephen
Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
title Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
title_full Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
title_fullStr Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
title_full_unstemmed Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
title_short Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
title_sort dose-escalation of human anti-interferon-α receptor monoclonal antibody medi-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978926/
https://www.ncbi.nlm.nih.gov/pubmed/24559157
http://dx.doi.org/10.1186/ar4492
work_keys_str_mv AT goldbergavram doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy
AT geppertthomas doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy
AT schiopuelena doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy
AT frechtracy doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy
AT hsuvivien doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy
AT simmsrobertw doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy
AT pengstanfordl doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy
AT yaoyihong doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy
AT elgeioushinairouz doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy
AT changlinda doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy
AT wangbing doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy
AT yoostephen doseescalationofhumanantiinterferonareceptormonoclonalantibodymedi546insubjectswithsystemicsclerosisaphase1multicenteropenlabelstudy